Light Mode
$9.33 ↑ +0.12 (+1.31%) Trading Up from the previous close of $9.21
+0.08 (+0.88%) / 6M
Momentum, market sentiment, and recent alerts
MGTX reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is +3.8%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
MeiraGTx Holdings Plc is a clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It targets local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet needs. The company was founded on March 20, 2015 and is headquartered in New York, NY.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.